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Abstract
Background: The estimated number of cigarette smokers in the world is 1.3 billion, expected to rise to 1.7
billion by 2025, with 10 million smokers living in the U.K. Smoking is the leading, preventable death-cause
worldwide, being responsible for almost 650,000 deaths in the E.U. annually. A combination of pharmacological
interventions, including nicotine replacement therapy, bupropion and varenicline, and behavioural support is the most
effective approach to smoking cessation. However, even the best methods have high relapse rates of approximately
75% within 6 months. Electronic (or “e-“) cigarettes use battery power to disperse a solution that usually contains
propylene glycol or glycerine, water, flavouring and nicotine. E-cigarettes have become the most popular smoking
cessation aid in England, however, information on their effects on cardiovascular function is limited and contradictory.
As e-cigarettes are not solely nicotine-based products, existing research exploring the effects of nicotine on
the cardio-vasculature provides only limited information, while their extensive uptake urges the need of
evidence to inform the general public, smokers and policy-makers.
Methods: This is a pragmatic, 3-group, randomised, assessor-blinded, single-centre trial exploring the cardiovascular
physiological effects of the use of e-cigarettes (nicotine-free and nicotine-inclusive, assessed separately) combined with
behavioural support as a smoking cessation method in comparison to the combination of NRT and behavioural
support. The primary outcome will be macro-vascular function, determined by a Flow Mediated Dilatation ultrasound
assessment, 6 months following participants’ “quit date”.
Discussion: Participants will be assessed at baseline, 3 days following their self-determined “quit date”, at intervention
end (3 months) and 6 months following their “quite date”. Findings are expected to give an indication of the
cardiovascular effects of e-cigarettes both in the short- and in the medium-term period, informing the general public,
policy holders and researchers, helping to define the future role of e-cigarettes as a smoking cessation aid.
Trial registration: Clinicaltrials.gov NCT03061253. Registered 17th February 2017.
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Background
The estimated number of cigarette smokers in the world is
1.3 billion, expected to rise to 1.7 billion by 2025, with 10
million smokers living in the U.K [1]. Smoking is the lead-
ing, preventable death-cause worldwide [2], being respon-
sible for almost 650,000 deaths in the E.U. annually [3].
Smoking cessation could reduce total cardiovascular dis-
ease (CVD) mortality by 36% [2]. This is because the vas-
cular endothelium plays a major role in cardiovascular
health and disease (e.g. systemic and pulmonary hyperten-
sion, coronary heart disease and stroke; [4], and cigarette
smoking has been associated with endothelial dysfunction
in otherwise healthy adults [5] – with its detrimental ef-
fects ranging from early functional endothelial alterations
to late clinico-pathological manifestations of atheroscler-
otic plaques [2]. The negative effects upon cardiovascular
function are not limited to smokers; passive smoking in-
creases heart disease death-risk by almost 30% [6].
A combination of pharmacological interventions, includ-
ing nicotine replacement therapy (NRT), bupropion and
varenicline, and behavioural support is the most effective
approach to smoking cessation [7, 8]. However, even the
best methods have high relapse rates of approximately 75%
within 6 months [7] and although they are offered as part
of the UK National Health Service (NHS), these interven-
tions have been reaching fewer smokers (down about 50%
from 2010/11 to 2015/16; [9]).
Cigarette smoke contains more than 9000 chemicals; the
vast majority of which are the products of tobacco combus-
tion [10]. The most important ones in regards to CVD risk
are: oxidizing chemicals, carbon monoxide, volatile organic
compounds, particulates, heavy metals and nicotine [11].
Therefore, and taking into consideration that nicotine is
highly addictive [11], it is important, where complete ab-
stinence is not possible, to encourage substitution of ciga-
rettes with “cleaner” nicotine-based products to reduce
CVD risk and reverse some of the smoking-induced
physiological damage [12].
Electronic (or “e-“) cigarettes or vaping devices uses bat-
tery power to disperse a solution that usually contains pro-
pylene glycol or glycerine, water, flavouring and nicotine
[13]. They have become the most popular smoking cessa-
tion aid in England [14], while evidence suggests that they
are efficacious as smoking cessation aids [15]. However,
data on their effects on cardiovascular function is limited
i.e. [16] and there is a lack of consensus within the smoking
cessation community as to their potential impact: conse-
quently, further research has been requested by the
European Parliament [17], the British Medical Association
[18], regulatory agencies, clinicians and researchers Lancet;
[19], BMC Public Health; [20]. As e-cigarettes are not solely
nicotine-based products, existing research exploring the ef-
fects of nicotine on the cardio-vasculature (e.g. coronary
and peripheral vasoconstriction, intravascular inflammation
and deregulation of cardiac autonomic function as well as
inhibition of microcirculation; [21]) provides only limited
information. Evidence is needed to inform the general pub-
lic, smokers and policy-makers.
This study aims to assess effects on cardiovascular
physiology in smokers making a quit attempt using e-
cigarettes (either nicotine-free or nicotine-inclusive) in
comparison with smokers making a quit attempt with
prescription NRT.
The specific objectives of the study include:
1. The comparison of the effects that nicotine-
inclusive e-cigarettes (Group A), nicotine-free
e-cigarettes (Group B) and NRT (Group C) have
on cardiovascular physiology both acutely (e.g.
within 3 days of “quit date”) and in the medium
term (6 months following “quit date”), by
measuring: a) endothelial-dependent, macro-
vascular function and b) endothelial-dependent,
micro-vascular function. The inclusion of Group
B (nicotine-free e-cigarettes), will allow us to
determine whether the e-cigarette vapour
constituents have a distinguishable effect on
cardio-vasculature against a nicotine-inclusive
e-cigarette (Group A).
2. Comparison of the effect of the different treatments
on cardiovascular disease risk.
3. An in-depth exploration of the participants’ study
experience in a sub-sample of participants.
4. Defining facilitators and barriers of smoking
cessation in each of the 3 groups.
5. Assessing the economic cost implications that the
approaches have on the NHS and the study
participants, by undertaking a Health Economics’
Cost Utility Analysis.
Methods
Design
A pragmatic, 3-group, randomised, assessor-blinded,
single-centre trial exploring the cardiovascular physio-
logical effects of the use of e-cigarettes (nicotine-free
and nicotine-inclusive, assessed separately) combined
with behavioural support as a smoking cessation method
in comparison to the combination of NRT and behav-
ioural support.
Study setting
All assessments will be undertaken at the Centre for
Sport and Exercise Science (CSES) of Sheffield Hallam
University. Behaviour support will be primarily provided
in Sheffield Hallam University premises in Collegiate
Crescent or City campuses to cover the widest possible
Sheffield population, with both locations being easily
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reached from all Sheffield areas. This setting was chosen
to ensure appropriate data collection, to assess its ac-
ceptance by participants and monitor their physical and
emotional wellbeing, as the university has extensive ex-
perience of delivering lifestyle interventions to clinical
populations (e.g. cancer, heart failure, aortic aneurysm,
chronic venous insufficiency and intermittent claudica-
tion). Group C will be referred to NHS smoking cessa-
tion clinics in Sheffield (Yorkshire Smokefree Sheffield),
provided by South West Yorkshire Partnership NHS
Foundation Trust.
Eligibility
Inclusion Criteria
– Age > 18 years of either sex,
– Smokers (at least 10 cigarettes/ day for the past
year),
– Willing (by declaration) to attempt quit smoking by
using the NHS services or e-cigarettes.
Exclusion Criteria
– Inability to walk,
– Recent (within 6 months) cardiovascular disease
event (e.g. stroke, myocardial infarction) or cardiac
surgery,
– Insulin-controlled diabetes mellitus or with
coexisting skin conditions, leg ulcers, vasculitis or
deep venous occlusion (as these may affect their
cardiovascular function),
– Pregnancy,
– Requiring major surgery during the course of the
study),
– Contraindications /unsuitability for NRT,
– Current daily use of e-cigarettes,
– Currently undertaking a cessation attempt
supported by a smoking cessation clinic,
– Unable to give informed consent.
Withdrawals.
Participants will be considered as withdrawn from the
trial if they request to leave the trial, if they are lost to
follow-up, or if they die before completing the 12-month
follow-up.
Participants will be considered as withdrawals from
the allocated treatment if they no longer use the elec-
tronic cigarette, or if they no longer receive NRT-based,
smoking cessation therapy. Withdrawals from the trial
and from the allocated treatment will be included in the
analysis by intention-to-treat. Standard care for partici-
pants who decide to withdraw from the study will not be
affected.
Recruitment and consent processes
Recruitment from the community in the wider Sheffield
area will be via: i) low-cost newspaper and post-office
advertisement, ii) posters in local pharmacies, libraries,
mosques, churches, and clubs, iii) social media or search
engine advertisement (Facebook, Google ads) iv) notices
in newsletters or participation in outreach events of
community organisations (such as Sheffield U3A and
AGE UK), iv) a study website and v) out-reach events in
local ethnic community centres or places of worship.
Potential participants will be provided with a study in-
formation pack by post, via e-mail or in person, contain-
ing an invitation letter (including also the contact details
of a research team member), a study information sheet
and a stamped, addressed envelope with a tear-off slip to
declare their interest (or not) to take part in the study.
Following receipt of an “expression of interest” slip/
phone call/e-mail, a researcher will contact the patient
by telephone and their first visit will be arranged.
Smokers who express interest and do not respond within
14 days of the research team posting them an informa-
tion sheet, will be contacted one more time. During Visit
1 written informed consent will be obtained and eligibil-
ity confirmed. The participant schedule for the study is
shown in the Fig. 1.
Resource use diary, randomisation and blinding
After completion of baseline assessments (Visit 1), par-
ticipants will receive the “resource use” diary together
with instructions as of how to complete it. The diary will
elicit information on utilisation of NHS and private
health care services related to smoking cessation or
smoking-related diseases and condition. It is proposed
to collects three items of information (1) number of
visits, (2) travel time and cost and (3) cost to the patient
for the following uses: (a) GP, (b) nurse at smoking ces-
sation clinics, (c) Nurse at smoking cessation clinics (d)
Psychologist/Counsellor. Similarly number of times and
the costs to the patient for undertaking (1) diagnostic
tests (X-rays, Blood test and any other tests) and (2)
medications (pain killers, sleeping pills, antibiotics, nico-
tine patches, any other) related to smoking cessation.
Further, number of days of hospitalisation related to
smoking related diseases will also be collected.
They be randomised remotely (to ensure allocation
concealment) into Groups A (using the nicotine-
inclusive e-cigarette), B (using the nicotine-free e-
cigarette) and C (being referred to NHS clinic), using a
computer programme (nQuery Advisor 6.0, Statistical
Solutions, Ireland) to generate stratified block-
randomization (by gender and “packet-years” (e.g. num-
ber of packs (20 cigarettes per pack)/day x number of
years smoked), by an independent statistician. Each
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participant will be allocated a unique trial number that
will remain with him/her throughout the study.
Outcome assessors will be blinded to group allocation
and participants will be reminded regularly not to share
their group allocation with this person. Statistician and
health economist will be blinded to group allocation
during the analysis process.
Sample size
For the purposes of sample size estimation the primary
outcome will be macro-vascular function, at 6-months
post-“quit date” follow-up, as measured by % Flow-
mediated dilatation FMD; [22]. For our calculations we
used commercial software (G*Power 3.1.7, HHU of
Düsseldorf ).
Based on the primary outcome and using data com-
paring the short-term effects of e-cigarettes on macro-
vascular function (measured by %FMD) in smokers and
non-smokers (S.D. in the smokers’ group prior to e-
cigarettes’ use = 3.23%, expected brachial FMD% differ-
ence between NRT group and e-cigarette users = 1.89%;
16). Using G*Power 3.1.7 (HHU of Düsseldorf ) we cal-
culated that we will need 66 participants in each group
to detect a difference in macro-vascular function at
6 months (significance level = 0.05; power = 80%). Ac-
counting for an estimated 25–30% dropout rate in-line
with other e-cigarette-based RCTs [15], we aim to re-
cruit 86 participants in each group (258 in total).
Intervention
All participants will be asked to define a “quit date”
(usually within a week of their baseline assessments or
their first appointment at the smoking cessation clinic if
in Group C, as per standard practice), on which they will
be asked to stop smoking completely. This will be noted
by the researcher and define follow-up visits.
Groups A and B will receive complimentary e-
cigarette equipment and refills (Tornado V5, Joyetech,
Shenzhen, China) at allocation stage, together with in-
structions on the correct usage of e-cigarettes. They will
also receive behavioural support for a 3-month period.
The nicotine strength of Group A cartridges will be up
Fig. 1 Participant study schedule
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to 18 mg/ml nicotine strength, Group B will receive
nicotine-free liquid.
Group C participants will be referred to NHS smoking
cessation clinics and receive NRT in conjunction with
behavioural support. Group C will be reimbursed for
their prescription charges for the intervention period.
It is impossible for all study participants to receive
behavioural support by the same person or at the
same venue as e-cigarettes are not part of the local
NHS strategy. To ensure that behavioural support is
comparable between groups, all groups will receive
the same level and type of behavioural support as
currently offered as standard at NHS smoking cessa-
tion clinics [23], in the form of regular face-to-face or
telephone appointments as per relevant guidelines
(e.G. minimum of 6 support sessions within the 3-
month period, offering practical advice and support,
as detailed and structured in reference [23]). All advi-
sors will have completed the same behavioural sup-
port training and will have previous NHS-based, SC
experience. Behavioural support sessions for Group A
and B will take place at easily-accessible locations
with a choice offered to participants to match the ser-
vice experience of Group C.
Follow-up visits
VISIT 2: Within 3 days of “quit date”, vascular assess-
ment of micro- and macro-vascular function (see
Outcomes).
VISIT 3: 3 months past quit date, scheduled to coin-
cide with current local NHS practice, all baseline mea-
surements will be repeated, compliance will be
measured in the resource use diaries as per NHS behav-
ioural support strategy [23].
VISIT 4: 6 months past quit date, baseline measure-
ments and compliance assessment will be repeated.
Measures
Baseline (Visit 1)
– Demographic data, including age and sex.
– Clinical history (including smoking history),
previous operations, comorbidities, current
medications, height, weight and blood pressure.
– FägerstromTest of Cigarette Dependence FTND; [24].
– EQ5D-5 L to support Health Economics’
assessment; [25].
– Q-Risk to assess risk of CVD; [26].
– Short Form (SF)- International Physical Activity
Questionnaire (IPAQ) to assess physical activity; [27].
– Macro-vascular function [22],
– Upper-body micro-vascular function [28],
– “Finger prick” test to calculate the total
cholesterol (TC) over High Density lipoprotein
(HDL) ratio [29].
– Carbon monoxide (CO) breath levels [30].
Outcome measures
The primary outcome will be macro-vascular function, a
well-established independent predictor of long-term ad-
verse cardiovascular events as determined by an FMD
assessment [22], 6 months following participants’ “quit
date”.
FMD is a non-invasive, nitric oxide-mediated measure,
which independently predicts long-term adverse cardio-
vascular events [12] and has been used in numerous
studies exploring smoking-induced physiological effects
i.e. [12, 16]. Baseline scanning to assess resting vessel
diameter will be recorded over 3 min, following a 10-
min resting period. The brachial artery will be imaged at
a location 3 to 7 cm above the antecubital crease to cre-
ate a flow stimulus in the brachial artery. A sphygmo-
manometric cuff will be placed on the forearm; the cuff
will be inflated at least 50 mmHg above systolic pressure
to occlude artery inflow for 5 min. Recordings will com-
mence 30s before cuff deflation and continuing for
3 min after. FMD will be expressed as a change in post-
stimulus diameter evaluated as a percentage of the base-
line diameter.
Secondary outcomes will include:
a) Micro- and macro-vascular function at 3 days to de-
fine acute treatment effects and 3 months (interven-
tions’ end).
Microvascular assessments using Laser Doppler
Fluximetry and Iontophoresis as described in the lit-
erature; [28] will be performed at all study visits, in a
temperature-controlled room (22–24 °C) in the ven-
tral surface of the experimental (right) arm extended
to the side at heart level. These will be used as indi-
cators of the changes occurring in the endothelial –
dependent and –independent vasodilatory function.
Heart rate (Sports Tester, Polar, Finland) and blood
pressure (left arm; Dinamap Dash 2500, GE Health-
care, USA) will be monitored at 5-min intervals
throughout the protocol. The two drug delivery elec-
trodes ((PF383; Perimed AB, Jarfalla, Sweden) will be
positioned over healthy looking skin, approximately
4 cm apart with one containing 100 μL of 1% acetyl-
choline (ACh; Miochol-E, Novartis, Stein) and the
other 100 μl of 1% sodium nitroprusside (SNP; Nitro-
prussiat, Rottapharm). A battery-powered iontophor-
esis controller (PeriIont PF382b; Perimed AB) will be
used to provide the charge needed for ACh and SNP
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delivery. A 4 min stable recording of baseline flux
will be followed by administration of the two agents
according to the following protocol: 0.2 mA for 10 s
(i.e., 2 mC), 0.2 mA for 15 s (i.e., 3 mC), 0.2 mA for
20 s (i.e., 4 mC), and 0.3 mA for 20 s (i.e., 6 mC),
happening between 4-min intervals. To obtain an
index of skin blood flow, cutaneous red cell flux will
be measured by placing an iontophoresis laser-
Doppler probe (PF481–1; Perimed AB), connected to
a laser Doppler fluxmeter (PF5001; Perimed AB).
b) Micro-vascular function at 6 months (measured as
described for a).
c) Smoking status at 3 and 6 months, self-reported and
biochemically validated by exhaled air measurement
of <10 ppm Carbon monoxide in line with the
Russell Standard [30].
d) change in CVD risk at 3 and 6 months compared
with baseline, measured using Q-risk
e) Health Economic effects (assessed using EQ5D-L
and a resource use diary) at 6 months. The EQ-
5D is a generic measure of health status, where
health is characterized on five dimensions (mobil-
ity, self-care, ability to undertake usual activities,
pain, anxiety/depression).The EQ-5D has been val-
idated in the UK and has been used in other
clinical trials i.e. [31].
f ) Total cholesterol (TC) and High Density lipoprotein
(HDL) via finger prick blood sample at 3 and
6 months; HDL is negatively affected by smoking
[29], and improvements in the TC/ HDL ratio can
be demonstrated 3 weeks after quitting [32].
Qualitative exploration
 We aim to explore the following topics:
 Factors that help smokers using e-cigarettes to quit
smoking and deter smokers using e-cigarettes from
quitting smoking, responding directly to a recent
Public Health England call for more research on
those areas [13].
 Experiences of treatment and advice given.
 Participant’s preference for trial allocation.
 Experiences of study participation
 Participant acceptability of the intervention and
study procedures.
 Methodological approach: Semi-structured in-
depth interviews conducted either face to face or
via telephone at 3-months post-group allocation
with twelve to sixteen participants recruited using
purposive sampling (mixture of genders, younger
and older participants from all three intervention
groups).
Data analysis
SPSS 21.0 will be used to enter quantitative data and
cleaning the data and to carry out missing values im-
putation and statistical analysis. Data will be reported
and presented according to the revised CONSORT
statement [33].
Analyses will be performed on an intention-to-treat
basis. Double data entry will be implemented to to pro-
mote data quality. Where applicable, tests will be two-
tailed with statistical significance being set at p ≤ 0.05.
Baseline demographic (i.e. age, gender, HSI), physical
measurements (e.g. weight, height, BMI), carbon monox-
ide and nicotine dependence levels, as well as Q-Risk,
SF-IPAQ and EQ5D-L will be assessed for comparability
between groups.
An Analysis of Variance (ANOVA) will be used to
compare mean macro- and micro-vascular function be-
tween groups. A 95% confidence interval (CI) for the
mean difference in these parameters between the three
groups will also be calculated. In the event of differences
between groups with respect to baseline measurements,
multiple regression will be used to adjust the treatment
effect for these variables, with the stratification covari-
ates being included in the analysis. The ordinary least
squares adjusted regression coefficient estimate for the
e-cigarette groups’ parameter, along with its 95% CI, will
then be reported. Secondary outcomes at 6-months will
be analysed similarly. For repeated assessments at base-
line, and at all follow-up sessions a summary measure
(e.g. “Area under the Curve”) will be calculated for each
participant.
Finally, a further subgroup analysis of those who
ceased smoking completely will be undertaken and re-
sults will be compared amongst the three groups.
For qualitative data analysis, audio recording of the in-
terviews will be made, transcribed verbatim, and the five
stages of framework analysis of familiarisation, identify-
ing a thematic framework, indexing, charting, and map-
ping will be followed [34, 35].
Further information on health economics’ analysis
We will undertake a comprehensive cost-utility analysis
with both NHS and societal perspectives. We will make
an assessment and valuation of costs (direct and indirect
costs) and benefits (QALY gains) as a result of the 3-
month smoking cessation intervention. The major cost
drivers will be patient’s use of NHS and private health
services, the patient’s time and their travel costs and
intervention delivery costs. To achieve this we will
calculate:
a. Cost of intervention (e.g. staff time, resources and
equipment used and room costs).
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b. Costs to participants (being based on the distance to
SHU or smoking cessation clinics and travel costs,
time taken-off from work to attend sessions and any
additional liquids or NRT-based medication bought
by participants).
c. Difference in resource use between groups (elicited
from the resource use diary).
d. Differences in patient experiences and health related
outcomes between intervention and control groups
(assessed via the EQ5D-5 L questionnaire, which
using the standardised general population based tar-
iff, would allow us to have its scores converted into
QALYs and then undertake a comparison between
study groups).
e. Incremental Cost-Effectiveness Ratio (ICER) (derived
from relating differences in costs to benefits between
study groups during the 6-month period).
We will use standard published sources for unit costs
where available and supplement this with local sources if
required. We will use imputation methods for missing
data, analysis of uncertainty and non-normal distribu-
tions: i.e. standard statistical analysis of costs will be per-
formed to test for statistical significance of results, while
bootstrapping would be performed to estimate the CI of
average interventional costs.
Safety monitoring
Study investigators will be responsible for recording ad-
verse events and for determining the seriousness, sever-
ity, causality and expectedness of any such events.
The study Primary Investigator will monitor patient
safety within the trial and will be responsible for review-
ing any adverse events occurring as part of the trial in
collaboration with a delegated clinician and confirming
that they have been appropriately classified.
Participants will be asked to contact the study team to
inform them about adverse events if and when they
occur. Study investigators will also question participants
about the occurrence of adverse events during each par-
ticipant study visit.
We will record all serious adverse events, as well as all
non-serious adverse events that are deemed to be related
to participation in the research, during the period be-
tween provision of informed consent through to
12 months after randomisation.
Serious adverse events are defined as any untoward
medical occurrence that results in one of the following
criteria:
– Results in death,
– Is life threatening (i.e. event in which patient is at
risk of death at the time of the event occurring),
– Requires unplanned or prolonged hospitalisation
(unplanned refers to emergency hospitalisations.
Prolonged hospitalisation is deemed to be where a
patient’s stay is longer than expected (e.g. patient is
operated on as day case but remains in hospital
overnight)
– Results in persistent or significant disability or
incapacity
A non-serious event in the context of this trial will be
any untoward medical occurrence to the participant that
is related to the participants’ involvement in the study,
but does not fulfil any of the serious adverse event
criteria.
Data handling and record keeping
The study will adhere to Data Protection Act (1998).
Data from this study will be anonymised and stored in
password protected computer systems accessible only by
the members of the research team, in order to guarantee
confidentiality to participants. Paper forms will be stored
in locked filing cabinets. All these will be kept in a se-
cured and continuously monitored building facilities
where the project will be conducted (Collegiate Hall,
Collegiate Crescent, Sheffield Hallam University). Study
material will remain in this location for data entry and
storage. Patient names will not be used to identify any
data. Instead, participants will be assigned a study identi-
fication number in order to anonymise their informa-
tion. All data will be anonymised according to the NHS
Code of Confidentiality and GMC Good Medical Prac-
tice while publications will not contain identifiable per-
sonal data. Furthermore, only research team members
will have access to participants’ personal data during the
project, while data will be analysed locally. Data will be
kept for a 7-year period following the study completion
to allow the study team to re-analyze it in case of the de-
velopment of a new method of analysis.
Discussion
Findings of this study, are expected to give an indication
of the cardiovascular effects of e-cigarettes both in the
short- and in the medium-term period. Our work will
inform the general public, policy holders and re-
searchers, helping to define the future role of e-
cigarettes as a smoking cessation aid.
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